Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05530343 · ClinicalTrials.gov registry record · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 2,298
- Enrollment target
- 14
- Study locations
NCT05530343: Recruiting NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by University of Colorado, Denver.
NCT05530343 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 2,298 participants, above the 255-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (801% higher). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05530343, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,298 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that is used to spot patients at increased risk of developing a type of cancer in the esophagus (swallowing tube) called esophageal adenocarcinoma. The 5-year survival rate is as low as 18% for patients who get esophageal adenocarcinoma, but the rate may be improved if the cancer is caught in its early stages. Barrett's esophagus can lead to dysplasia, or precancerous changes, which occurs when cells look abnormal but have not developed into cancer. If the abnormal cells increase from being slightly abnormal (low-grade dysplasia), to being very abnormal (high-grade dysplasia), the risk of developing cancer (esophageal adenocarcinoma) goes up. Therefore, catching dysplasia early is very important to prevent cancer. Endoscopic surveillance is a type of procedure where endoscopists run a tube with a light and a camera on the end of it down a patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Patients are being asked to be in this research study because they have been diagnosed with BE or suspected to have BE, and will need an esophagogastroduodenoscopy (EGD). Patients with BE undergo sampling using the Seattle biopsy protocol during which samples are obtained from the BE in a four quadrant fashion every 2 cm along with target biopsies from any abnormal areas within the BE. Another sampling approach is WATS3D which utilizes brushings from the BE. While both of these procedures are widely accepted approaches to sampling patients with BE during endoscopy, there is not enough research to show if one is better than the other. Participants in
Primary Outcome
Proportion of positive results between the Seattle protocol and WATS3D technique. Positive results include low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). All positive results for dysplasia or EAC with WATS3D sampling not detected on Seattle biopsy protocol at index endoscopy will require confirmation by repeat sampling using the Seattle biopsy protocol.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Seattle protocol
- DIAGNOSTIC_TEST WATS3D brushings
Study Locations (14)
New York
- Long Island Jewish Medical Center - New Hyde Park
- Weill Cornell Medicine - New York
- University of Rochester - Rochester
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Oakland
Arizona
- Arizona Centers of Digestive Health - Gilbert
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- Connecticut Clinical Research Institute - Bristol
Florida
- Suncoast Endoscopy of Sarasota - Sarasota
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,298 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT05530343 shows while recruiting
NCT05530343 is an interventional study that assigns participants to a tested intervention. Its 2,298 participants enrollment target places it among the larger protocols in the corpus, above the 255-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (801% higher).
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Seattle protocol is the first listed.
NCT05530343 lists 14 locations in 11 states (New York, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT05530343 about?
NCT05530343 is a clinical study titled "Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance". The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that ...
What is the current status of trial NCT05530343?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,298 participants. The study started on 2022-10-03. Estimated completion is 2026-03.
What conditions does trial NCT05530343 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Barretts Esophagus With Dysplasia.
What interventions are being tested in trial NCT05530343?
The interventions under investigation include: Seattle protocol (DIAGNOSTIC_TEST), WATS3D brushings (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05530343?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05530343 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05530343's enrollment target sits among peer trials
2,298 2nd of 43 the highest of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
- NCT05759988 · 2,300 participants · NA
Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI